Brigitte Schurch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9558472/publications.pdf

Version: 2024-02-01

40 papers	4,733 citations	318942 23 h-index	340414 39 g-index
41 all docs	41 docs citations	41 times ranked	2808 citing authors

#	Article	IF	Citations
1	Urodynamics in patients with multiple sclerosis: A consensus statement from a urodynamic experts working group. Neurourology and Urodynamics, 2020, 39, 73-82.	0.8	10
2	Alphaâ€blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and metaâ€analysis. A report from the Neuroâ€Urology Promotion Committee of the International Continence Society (ICS). Neurourology and Urodynamics, 2019, 38, 1482-1491.	0.8	11
3	Are there different patterns of detrusor overactivity which are clinically relevant? ICIâ€RS 2018. Neurourology and Urodynamics, 2019, 38, S40-S45.	0.8	3
4	How can we better manage drugâ€resistant OAB/DO? ICIâ€RS 2018. Neurourology and Urodynamics, 2019, 38, S46-S55.	0.8	6
5	Conditional neuromodulation of neurogenic detrusor overactivity using transrectal stimulation in patients with spinal cord injury: A proof of principle study. Knight SL, Edirisinghe N, Leaker B, Susser J, Craggs MD, Neurourol Urodyn. 2017 Jun 30. Neurourology and Urodynamics, 2018, 37, 1507-1508.	0.8	0
6	The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICIâ€RS 2017 think thank, Bristol. Neurourology and Urodynamics, 2018, 37, S99-S107.	0.8	19
7	Longâ€term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourology and Urodynamics, 2018, 37, 799-806.	0.8	29
8	An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourology and Urodynamics, 2018, 37, 1152-1161.	0.8	170
9	Urodynamics in patients with spinal cord injury: A clinical review and best practice paper by a working group of The International Continence Society Urodynamics Committee. Neurourology and Urodynamics, 2018, 37, 581-591.	0.8	18
10	Targeted neurotechnology restores walking in humans with spinal cord injury. Nature, 2018, 563, 65-71.	13.7	708
11	Screening for urinary incontinence in acute care for elders unit: comparative performance analysis of Katzâ€™s ADL and ICIQ-UI-SF. European Geriatric Medicine, 2018, 9, 579-588.	1.2	1
12	What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICIâ€RS 2017. Neurourology and Urodynamics, 2018, 37, S108-S116.	0.8	22
13	Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. World Journal of Urology, 2017, 35, 307-311.	1.2	37
14	Long-term compliance and results of intravesical botulinum toxin A injections in male patients. Neurourology and Urodynamics, 2017, 36, 1855-1859.	0.8	24
15	A multidirectional gravity-assist algorithm that enhances locomotor control in patients with stroke or spinal cord injury. Science Translational Medicine, 2017, 9, .	5.8	42
16	Treatment Failure of Botulinum Toxin A in Patients with Idiopathic Overactive Bladder: Why Do Patients Discontinue Treatment?. Nephro-Urology Monthly, 2017, Inpress, .	0.0	1
17	Supraspinal Control of Urine Storage and Micturition in Menâ€”An fMRI Study. Cerebral Cortex, 2015, 25, 3369-3380.	1.6	52
18	Dysfunction of lower urinary tract in patients with spinal cord injury. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 130, 247-267.	1.0	18

#	Article	IF	Citations
19	OnabotulinumtoxinA and multiple sclerosis. Annals of Physical and Rehabilitation Medicine, 2014, 57, 302-314.	1.1	23
20	What treatment should we use if drugs fail for OAB; and, what really works after drugs?. Neurourology and Urodynamics, 2010, 29, 658-661.	0.8	10
21	Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report. European Urology, 2009, 55, 100-120.	0.9	269
22	A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World Journal of Urology, 2009, 27, 397-403.	1.2	58
23	Botulinum Toxin A (BotoxÂ®) Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Literature Review. European Urology, 2008, 53, 275-287.	0.9	258
24	Reliability and Validity of the Incontinence Quality of Life Questionnaire in Patients With Neurogenic Urinary Incontinence. Archives of Physical Medicine and Rehabilitation, 2007, 88, 646-652.	0.5	113
25	Botulinum Toxin A Improves the Quality of Life of Patients with Neurogenic Urinary Incontinence. European Urology, 2007, 52, 850-859.	0.9	93
26	Do Repeat Intradetrusor Botulinum Toxin Type A Injections Yield Valuable Results? Clinical and Urodynamic Results after Five Injections in Patients with Neurogenic Detrusor Overactivity. European Urology, 2007, 52, 1729-1735.	0.9	90
27	A case of undiagnosed tethered cord syndrome aggravated by transurethral prostate resection. Nature Reviews Urology, 2005, 2, 199-204.	1.4	3
28	Can neurologic examination predict type of detrusor sphincter-dyssynergia in patients with spinal cord injury?. Urology, 2005, 65, 243-246.	0.5	43
29	Understanding detrusor sphincter dyssynergiaâ€"significance of chronology. Urology, 2005, 66, 763-768.	0.5	24
30	BOTULINUM TOXIN TYPE A IS A SAFE AND EFFECTIVE TREATMENT FOR NEUROGENIC URINARY INCONTINENCE: RESULTS OF A SINGLE TREATMENT, RANDOMIZED, PLACEBO CONTROLLED 6-MONTH STUDY. Journal of Urology, 2005, 174, 196-200.	0.2	532
31	Lack of Ultrastructural Detrusor Changes Following Endoscopic Injection of Botulinum Toxin Type A in Overactive Neurogenic Bladder. European Urology, 2004, 46, 784-791.	0.9	176
32	Treatment of Neurogenic Incontinence with Botulinum Toxin A. New England Journal of Medicine, 2000, 342, 665-665.	13.9	212
33	BLADDER NECK INCOMPETENCE IN PATIENTS WITH SPINAL CORD INJURY: SIGNIFICANCE OF SYMPATHETIC SKIN RESPONSE. Journal of Urology, 2000, 163, 1223-1227.	0.2	37
34	BOTULINUM-A TOXIN FOR TREATING DETRUSOR HYPERREFLEXIA IN SPINAL CORD INJURED PATIENTS: A NEW ALTERNATIVE TO ANTICHOLINERGIC DRUGS? PRELIMINARY RESULTS. Journal of Urology, 2000, 164, 692-697.	0.2	741
35	BOTULINUM-A TOXIN FOR TREATING DETRUSOR HYPERREFLEXIA IN SPINAL CORD INJURED PATIENTS: A NEW ALTERNATIVE TO ANTICHOLINERGIC DRUGS? PRELIMINARY RESULTS. Journal of Urology, 2000, 164, 692-697.	0.2	267
36	Assessment of autonomic dysreflexia in patients with spinal cord injury.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 473-477.	0.9	175

#	Article	IF	Citations
37	Recovery of bladder function in patients with acute spinal cord injury: significance of ASIA scores and somatosensory evoked potentials. Spinal Cord, 1997, 35, 368-373.	0.9	56
38	Botulinum-A Toxin as a Treatment of Detruosor-Sphincter Dyssynergia: A Prospective Study in 24 Spinal Cord Injury Patients. Journal of Urology, 1996, 155, 1023-1029.	0.2	297
39	Detrusor Bladder Neck Dyssynergia Revisited. Journal of Urology, 1994, 152, 2066-2070.	0.2	67
40	Botulinum neurotoxin applications in urological disorders. , 0, , 288-294.		0